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Summary
Background Severe anaemia is a leading cause of paediatric admission to hospital in Africa; post-discharge outcomes 
remain poor, with high 6-month mortality (8%) and re-admission (17%). We aimed to investigate post-discharge 
interventions that might improve outcomes.
Methods Within the two-stratum, open-label, multicentre, factorial randomised TRACT trial, children aged 2 months 
to 12 years with severe anaemia, defined as haemoglobin of less than 6 g/dL, at admission to hospital (three in 
Uganda, one in Malawi) were randomly assigned, using sequentially numbered envelopes linked to a second non-
sequentially numbered set of allocations stratified by centre and severity, to enhanced nutritional supplementation 
with iron and folate-containing multivitamin multimineral supplements versus iron and folate alone at treatment 
doses (usual care), and to co-trimoxazole versus no co-trimoxazole. All interventions were administered orally and 
were given for 3 months after discharge from hospital. Separately reported randomisations investigated transfusion 
management. The primary outcome was 180-day mortality. All analyses were done in the intention-to-treat population; 
follow-up was 180 days. This trial is registered with the International Standard Randomised Controlled Trial registry, 
ISRCTN84086586, and follow-up is complete.
Findings From Sept 17, 2014, to May 15, 2017, 3983 eligible children were randomly assigned to treatment, and followed 
up for 180 days. 164 (4%) were lost to follow-up. 1901 (95%) of 1997 assigned multivitamin multimineral supplement, 
1911 (96%) of 1986 assigned iron and folate, and 1922 (96%) of 1994 assigned co-trimoxazole started treatment. By day 
180, 166 (8%) children in the multivitamin multimineral supplement group versus 169 (9%) children in the iron and 
folate group had died (hazard ratio [HR] 0·97, 95% CI 0·79–1·21; p=0·81) and 172 (9%) who received co-trimoxazole 
versus 163 (8%) who did not receive co-trimoxazole had died (HR 1·07, 95% CI 0·86–1·32; p=0·56). We found no 
evidence of interactions between these randomisations or with transfusion randomisations (p>0·2). By day 180, 
489 (24%) children in the multivitamin multimineral supplement group versus 509 (26%) children in the iron and folate 
group (HR 0·95, 95% CI 0·84–1·07; p=0·40), and 500 (25%) children in the co-trimoxazole group versus 498 (25%) children 
in the no co-trimoxazole group (1·01, 0·89–1·15; p=0·85) had had one or more serious adverse events. Most serious 
adverse events were re-admissions, occurring in 692 (17%) children (175 [4%] with at least two re-admissions). 
Interpretation Neither enhanced supplementation with multivitamin multimineral supplement versus iron and 
folate treatment or co-trimoxazole prophylaxis improved 6-month survival. High rates of hospital re-admission 
suggest that novel interventions are urgently required for severe anaemia, given the burden it places on overstretched 
health services in Africa. 
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Introduction
Severe anaemia, defined as haemoglobin of less than 
6 g/dL, is a leading cause of hospital admission 
and mortality in children in sub-Saharan Africa.1–4 Out-
comes remain unsatisfactory, with high rates of reported 
in-hospital mortality (9–10%);2,3 however, long-term out-
comes are also poor, with high additional mortality (8%), 
anaemia relapse (6%), and re-admission (17%) by 6 months 
after discharge.4 Thus, transfusion alone might not be 
sufficient to achieve optimal outcomes for these children.
Anaemia is often multifactorial, with several cofactors 
related to mortality risk. In a comprehensive case-control 
study of children admitted to hospital with severe 
anaemia in Africa,3 bacteraemia, malaria, hookworm, 
HIV, or vitamins A and B12 deficiency, or all six, 
were key associations. Both iron and folate deficiencies 
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were less prevalent among cases than controls, and 
neither were associated with mortality.4 Because WHO 
already recommend iron, folate, and anthelmintics after 
discharge for children admitted with severe anaemia,5 the 
clearest potentially modifiable underlying causes of late 
anaemia recurrence are additional nutritional factors and 
recurrent bacterial infections. Multivitamin multimineral 
supplement Nutromix, also known as sprinkles, are 
widely available globally and offer a low-risk strategy for 
correcting underlying nutritional anaemia.6,7 Similarly, co-
trimoxazole prophylaxis has shown mortality benefits 
(with extremely low rates of toxicity) in children infected 
with HIV,8,9 generally attributed to reductions in bacterial 
infections, even in areas of high background resistance.10,11 
Co-trimoxazole might therefore reduce the occurrence 
of bacterial infections after severe anaemia. However, 
whether this would affect re-admission or mortality is 
unclear, particularly because it did not improve outcomes 
after hospital admission for severe malnutrition.12 
We assessed whether multivitamin multimineral 
supplement or co-trimoxazole prophylaxis given for 
3 months after hospital discharge in children admitted 
for severe anaemia (<6 g/dL) could prevent long-term 
mortality and re-admission in African children. The 
results of the transfusion randomisations are reported 
separately.13,14 
Methods
Study design and participants
From Sept 17, 2014, to May 15, 2017, we enrolled children 
into a two-stratum, open-label, multicentre, factorial 
randomised trial in Uganda (three hospitals) and Malawi 
(one hospital). Eligible children were aged 2 months to 
12 years, presenting to hospital with severe anaemia, 
defined as haemoglobin of less than 6 g/dL. Children 
with known chronic diseases (renal or liver failure, 
malignancies, heart failure, or congenital heart disease) 
or with burns or trauma, and infants who were exclusively 
Research in context 
Evidence before this study
Currently there are no specific recommendations for infection 
prophylaxis in African children admitted to hospital with severe 
anaemia that address the high mortality and re-admission rate 
in the high-risk period after discharge period (3–6 months). 
A trial in Malawi considered 90 days of malaria 
chemoprevention consisting of three treatment courses of 
artemether-lumefantrine (in hospital, and 1 month and 
2 months after discharge) for children younger than age 5 years. 
In the 180 days after discharge, deaths or re-admissions were 
reduced by 31%. In two trials in The Gambia, malaria 
chemoprevention during the malaria transmission season in 
children admitted to hospital with severe anaemia reduced 
clinical malaria by half and all-cause hospital re-admission 
by 78%. No trials have investigated antibacterial 
chemoprophylaxis for African children admitted to hospital 
with severe anaemia.
The use of iron supplements in Africa is an area of controversy, 
with a number of observational studies and community-based 
clinical trials suggesting that iron might increase the risk of 
malaria. In 2013, a controlled trial showed no increased risk of 
malaria or hospitalisation for iron-treated children in 
malaria-endemic Africa. Children included in this trial were 
enrolled in the community, tested and treated for malaria, 
and received insecticide-treated bednets. Following a Cochrane 
review in 2016, WHO now recommends iron can be administered 
without screening for anaemia or for iron deficiency (if resources 
do not permit), as long as malaria prevention or efficient 
management services, or both, are available.
No trial has considered the optimal iron treatment or 
supplemental strategy for children following admission to 
hospital with severe anaemia (who might have received an 
iron-rich transfusion) even though WHO recommends all 
children should receive a 90-day course of iron and folate 
(alongside anthelminth treatment).
Added value of this study
Our findings highlight the burden that severe anaemia places 
on health services in Africa, given the substantial proportion of 
children with severe anaemia that were re-admitted (~17%) to 
hospital or died (~9%) within the next 6 months, with 
infectious causes being the main cause of admission. Neither 
the use of multivitamin multimineral supplement or 
co-trimoxazole improved poor outcomes in children after 
discharge from hospital. Because we were able to examine the 
dose of iron, and found the haemoglobin recovery was similar 
at all doses of iron and even in children who did not receive a 
transfusion, our trial also raises questions about whether iron 
supplementation improves outcomes. We also found no 
evidence of increased risk of adverse outcomes in those 
receiving iron without concomitant antimalarial prophylaxis.
Implications of all the available evidence
This is the first time that co-trimoxazole, as infection 
prophylaxis, and MVMM, as a nutritional supplement, have 
been tested in a clinical trial in children hospitalised with severe 
anaemia. Our findings suggest that neither multivitamin 
multimineral supplements nor co-trimoxazole should be 
provided to children after discharge from hospital after severe 
anaemia. Our findings also raise questions about whether iron 
supplementation is beneficial at all in this population. They also 
challenge the current recommendation advising to give iron 
therapy or supplementation to children in malarious areas only 
if children are receiving malaria prophylaxis. The longer-term 
morbidity burden experienced by children with severe anaemia 
suggests that future trials should focus on strategies to prevent 
these adverse outcomes, particularly re-admissions. 
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breast fed were excluded.15 In stratum A, children with 
severe and complicated anaemia (haemoglobin <4 g/dL 
[profound anaemia]) or haemoglobin of less than 6 g/dL 
plus one or more signs of severity or complications 
(reduced consciousness [ie, coma or prostration], 
respiratory distress, acute haemoglobinuria or known 
sickle cell disease) were randomly assigned (1:1) to 
transfusion with 30 mL/kg versus 20 mL/kg whole 
blood (15 vs 10 mL/kg settled or packed cells, denoted 
whole blood equivalent). In stratum B, children with 
uncomplicated severe anaemia (haemoglobin 4–6 g/dL 
without any severity signs/complications) were randomly 
assigned 1:1:2 to immediate whole blood equivalent 
30 mL/kg versus 20 mL/kg versus no immediate 
transfusion (control:standard of care) unless or until 
severity criteria were met).15 We have previously described 
the blood packs used in the trial.16 At the same time, 
children in both strata were randomly assigned using a 
factorial design to receive 3 months of co-trimoxazole 
prophylaxis or not, and to 3 months of multivitamin 
multimineral supplement supplementation (containing 
10 mg iron as microencapsulated ferrous folate and 
150 µg folic acid daily for all ages) versus 3 months of 
standard treatment with iron (either 25 mg iron for 
children <2 years or 60 mg iron for children ≥2 years) 
and folate (100–400 µg, depending on the local for-
mulation used as standard-of-care at sites). The multi-
vitamin multimineral supplement also contained 
vitamins A, B1 (thiamine), B2 (riboflavin), B3 (niacin), 
B6, B12, C, D, zinc, copper, selenium, and iodine, in 
addition to folic acid and iron (doses, recommended 
nutrient intake [RNI] for iron,17 and is included in 
the appendix (p 4); provided by Hexagon Nutrition 
(Exports) Private, Chenai, India). Nutritional treatments 
or supplements, or both, and co-trimoxazole were 
prescribed to be given orally once daily, at discharge or 
from 5 days post admission for children with extended 
length of stay. Intake was not supervised, but adherence 
was monitored through pill counts and self-reports of 
missed pills at follow-up visits. Where previous written 
consent from parents or legal guardians could not be 
obtained, ethics committees approved verbal assent with 
delayed written informed consent as soon as practicable.18 
The ethics committees of Imperial College London 
(London, UK), Makerere University (Kampala, Uganda), 
and the College of Medicine (Blantyre, Malawi) approved 
the protocol. 
Randomisation and masking 
Children with suspected severe anaemia based on 
presenting symptoms and signs (eg, severe pallor19) 
were screened using a rapid bedside test (HemoCue 
Hb301 system; HemoCue AB, Angelholm, Sweden20) to 
determine haemoglobin concentration, and clinically 
assessed for severity, including history of passing dark 
or red urine (haemoglobinuria)21 or known sickle cell 
disease. Randomisation was stratified by clinical centre 
and complicated versus uncomplicated severe anaemia. 
The trial statistician at the Medical Research Council 
(MRC) Clinical Trials Unit (London, UK) generated and 
kept the computer-generated sequential randomisation 
list, generated using variably sized permuted blocks. 
Trial numbers and randomised allocations were kept 
inside opaque sealed envelopes (packed at Kilifi, 
Kenya), together with separate consecutively numbered 
packs containing case record forms. The link between 
pack number and trial number was randomised within 
blocks. At enrolment, trial staff opened the next 
consecutively numbered pack, which directed them 
to a sealed randomisation envelope that was within the 
next 16 envelopes, but was not the next one, ensuring 
allocation concealment.
An open-label design was used for multivitamin 
multimineral supplement because the comparator was 
standard-of-care iron and folate prescribed from local 
stocks and it was not possible to create an equivalent iron 
and folate formulation to the active multivitamin multi-
mineral supplement. There was no placebo multivitamin 
multimineral supplement formulation available, so a 
double-dummy approach was not feasible. There was 
also no placebo readily available for the co-trimoxazole 
formulation donated to the trial. Because children 
were already being randomly assigned to multivitamin 
multimineral supplement versus iron and folate and to 
co-trimoxazole or not, and as the primary endpoint was 
objective (mortality) and many secondary endpoints were 
also objective (laboratory values) or severe (re-admission, 
serious adverse events), masking was not considered 
essential. The open-label design also allowed the trial to 
assess real-world adherence. Nurses and doctors were 
unmasked, but the laboratory tests were done blind to 
randomisation groups.
Procedures
Children were managed on general paediatric wards 
where ventilation facilities were unavailable. Training 
and basic infrastructural support for emergency care, 
bedside capillary haemoglobin (HemoCue Hb301 
which was quality-controlled daily), glucose and lactate 
point-of-care tests, and patient monitors were provided. 
Blood transfusions were free of charge, from the local 
blood transfusion services, prescreened for standard 
transfusion transmissible infections16 (but not for 
malaria) and prepared using standard procedures, but 
did not include leucocyte reduction.22 Other than the 
transfusion randomisation, all children received standard 
treatments following national guidelines,23,24 including 
anthelmintics. 
A structured case report form was completed at 
admission and at reviews every 30 min during 
transfusion, then regularly (at 2 h, 4 h, 8 h, 16 h, 24 h, and 
daily thereafter) during admission. Haemoglobin was 
assessed using Hemocue every 8 h in the first 24 h, and 
daily thereafter. After discharge, children were routinely 
For the protocol see 
https://www.ctu.mrc.ac.uk/
media/1301/tract-protocol-v10-
20-feb-2013.pdf
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followed up on days 28, 90, and 180 after randomisation 
for review of clinical status and haemoglobin 
measurements. Children exited the trial at 180 days. 
Serious adverse events were actively solicited at every 
assessment. 
Outcomes
The primary outcome was mortality through 180 days 
from randomisation, censoring at the minimum of last 
ascertainment of vital status (intended to be at the 
180-day visit) and 183 days (6 months). Secondary 
Figure 1: Trial profile
All children for whom co-trimoxazole prophylaxis should have been prescribed according to WHO or national guidelines (eg, HIV-infected children) received it 
regardless of randomisation. 
6171 children screened
3986 randomised
1000 randomly assigned to 
multimineral multivitamins 
and co-trimoxazole
998 randomly assigned to 
multimineral multivitamins 
only
1 declined written consent 
after verbal assent
2185 excluded
1415 not anaemic
329 not able or willing to give consent
102 unable to commit to follow-up
93 no blood available
54 not in age range
50 terminal illness or renal, liver, or heart failure
34 breastfeeding
31 severity feature, but enrolment had closed
19 admitted for surgery
5 died during screening
53 reason missing
995 randomly assigned to iron and 
folate and co-trimoxazole
1 declined written consent 
after verbal assent
993 randomly assigned to iron and 
folate only
950 received multimineral 
multivitamins
36 died or absconded before 
prescription
4 contraindications
10 receiving alternative 
nutrition
963 received co-trimoxazole 
34 died or absconded before 
prescription 
3 contraindications
951 received multimineral 
multivitamins
33 died or absconded before 
prescription
4 contraindications
9 receiving alternative 
nutrition
27 received co-trimoxazole 
27 were HIV positive
958 received iron and folate
32 died or absconded before 
prescription
4 contraindications
959 received co-trimoxazole
32 died or absconded before 
prescription 
3 contraindications
953 received iron and folate
32 died or absconded before 
prescription
7 contraindications
29 received co-trimoxazole 
28 were HIV positive
1 had prescription <7 days
38 lost to follow-up by 180 days 
(29 received multimineral 
multivitamins, 29 received 
co-trimoxazole)
1 withdrew
7 moved away
3 lost interest in trial
27 could not be traced
45 lost to follow-up by 180 days 
(36 received multimineral 
multivitamins, 2 received 
co-trimoxazole) 
2 lost interest in trial
3 withdrew
6 moved away
34 could not be traced  
45 lost to follow-up by 180 days  
(43 received iron and folate, 
43 received co-trimoxazole)
7 moved away
3 lost interest in trial
2 social problems
1 transport problems
 32 could not be traced  
36 lost to follow-up by 180 days 
(34 received iron and folate, 
0 received co-trimoxazole) 
1 withdrew
5 moved away
1 lost interest in trial
29 could not be traced  
1 declined written consent 
after verbal assent
80 died (55 received 
multimineral multivitamins, 
58  received co-trimoxazole)
86 died (64 received 
multimineral multivitamins, 
4 received co-trimoxazole)
92 died (63 received iron and 
folate, 64 received 
co-trimoxazole)
77 died (52 received iron and 
folate, 5 received 
co-trimoxazole)
1000 included in 
intention-to-treat analyses
997 included in intention-to-treat 
analyses
994 included in intention-to-treat 
analyses
992 included in intention-to-treat 
analyses
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outcomes were mortality at 28 days and 90 days, 
development of severe anaemia after discharge, re-
admission to hospital, proportion achieving correction of 
anaemia (defined by WHO as >9 g/dL), changes in 
weight and MUAC, at 90 days and 180 days (nutrition), 
incidence of bacterial infections and malaria overall and 
at days 28, 90, and 180, serious adverse events, grade 3–4 
toxicity of co-trimoxazole, multivitamin multimineral 
supplement or standard iron and folate,15 and costs and 
cost-effectiveness. Adverse events were graded using 
the Common Toxicity Criteria for Adverse Events, 
version 4.0.25 An independent endpoint review committee 
reviewed all deaths masked to randomised group. 
Statistical analysis
3954 children provided more than 80% power to detect a 
5% absolute reduction in 180-day mortality in children 
randomly assigned to enhanced supplementation (multi-
vitamin multimineral supplement or co-trimoxazole) 
versus standard treatment (iron and folate or no co-
trimoxazole; from 25% to 20%), assuming 6% loss to 
follow-up at 180 days, with two-sided α of 0·013 to allow for 
four comparisons (appendix p 5). Interim data were 
reviewed by an independent data monitoring committee 
(three annual meetings) using Haybittle-Peto criterion 
(p<0·001). Randomised groups were compared following 
intention to treat, using log-rank tests or competing-risks 
MVMM (N=1997) Iron and folate 
(N=1986)
Co-trimoxazole 
(N=1994)
No co-trimoxazole
(N=1989)
Total (N=3983)
Age, months 36 (17–61) 34 (16–62) 36 (18–63) 34 (17–61) 35 (17–61)
Sex
Female 848 (42%) 880 (44%) 855 (43%) 873 (44%) 1728 (43%)
Male 1149 (58%) 1106 (56%) 1139 (57%) 1116 (56%) 2255 (57%)
Haemoglobin, g/dL 4·5 (3·6–5·4) 4·5 (3·6–5·3) 4·5 (3·6–5·3) 4·5 (3·6–5·3) 4·5 (3·6–5·3)
Weight, kg 11·9 (9·0–15·6) 11·7 (8·9–15·5) 12·0 (9·0–16·0) 11·5 (8·9–15·3) 11·8 (9·0–15·6)
MUAC, cm 14·5 (13·5–15·5) 14·5 (13·5–15·5) 14·5 (13·5–15·5) 14·5 (13·5–15·5) 14·5 (13·5–15·5)
Severe malnutrition* 31 (2%) 44 (2%) 28 (1%) 47 (2%) 75 (2%)
Undernourished† 84 (4%) 97 (5%) 95 (5%) 86 (4%) 181 (5%)
Heart rate, beats per minute 146 (130–160) 146 (131–160) 146 (130–160) 146 (131–160) 146 (131–160)
History of fever in this illness 1937 (97%) 1926 (97%) 1937 (97%) 1926 (97%) 3863 (97%)
Axillary temperature‡ at screening 37·2 (36·7–37·9) 37·3 (36·7–38·0) 37·3 (36·7– 38) 37·3 (36·7– 37·9) 37·3 (36·7–38·0)
Fever, >37·5°C 729 (37%) 793 (40%) 776 (39%) 746 (38%) 1522 (38%)
Hypothermia, <36·0°C 72 (4%) 75 (4%) 72 (4%) 75 (4%) 147 (4%)
Oxygen saturation 97% (95–99) 98% (95–99) 98% (95–99) 97% (95–99) 97% (95–99)
Respiratory rate, breaths per minute 40 (33–50) 41 (34–50) 40 (33–50) 41 (34–50) 40 (33–50)
Shock§ 572 (29%) 598 (30%) 569 (29%) 601 (30%) 1170 (29%)
Severe dehydration (skin turgor or 
sunken eyes)
135 (7%) 134 (7%) 123 (6%) 146 (7%) 269 (7%)
HIV positive 58/1901 (3%) 57/1884 (3%) 57/1901 (3%) 58/1884 (3%) 115/3785 (3%)
Malaria slide or RDT positive 1262 (63%) 1275 (64%) 1288 (65%) 1249 (63%) 2537 (64%)
Positive blood culture 59/1726 (3%) 66/1721 (4%) 54/1719 (3%) 71/1728 (4%) 125/3447 (4%)
C-reactive protein (mg/dL) 59 (21·1–111·7) 62·3 (24·4–112·9) 61·2 (21·1–111·7) 59·8 (24–113·8) 60·4 (22·7–112·3)
Any severity feature 1217 (61%) 1204 (61%) 1210 (61%) 1211 (61%) 2421 (61%)
Reported sickle cell disease (at 
screening)
259 (13%) 207 (10%) 232 (12%) 234 (12%) 466 (12%)
Sickle cell disease genotyping¶ 542/1980 (27%) 512/1964 (26%) 538/1973 (27%) 518/1971 (26%) 1054/3944 (27%)
Reported sickle cell; positive 
genotype
241 (12%) 190 (10%) 217 (11%) 214 (11%) 431 (11%)
Undiagnosed, sickle cell-positive 
genotype
301 (15%) 322 (16%) 319 (16%) 304 (15%) 623 (16%)
Country
Uganda 1764 (88%) 1765 (88%) 1763 (88%) 1757 (88%) 3520 (88%)
Malawi 233 (12%) 230 (12%) 231 (12%) 232 (12%) 463 (12%)
Data are n (%), median (IQR), or n/N (%). MMVM=multivitamin multimineral supplements. MUAC=mid-upper arm circumference. RDT=rapid diagnostic test. Weight for 
height Z score=WHZ. WAZ=weight for age Z score. *One or more of MUAC <11·0 cm (children aged 2–6 months) or MUAC <11·5 cm (children aged 6–59 months) or WHZ less 
than –3 (or WAZ if height not recorded) or presence of kwashiorkor at any age. †One or more of MUAC ≥11·0–11·9 cm (children aged 2–6 months) or MUAC ≥11·5–12·4 cm 
(children aged 6–59 months) or WHZ –3 to –2 (or WAZ if height not recorded) at any age. ‡Measured using a digital thermometer. §Any one of capillary refill time >2 s, 
temperature gradient or weak pulse. ¶From batch genotyping at Kilifi (on samples taken at baseline) after the end of the trial. 39 children had missing results.
Table 1: Baseline characteristics
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methods for time-to-event outcomes, exact tests for binary 
outcomes, and generalised estimating equations, with 
independent working correlation for global tests of 
repeated measures (normal distribution for continuous 
outcomes, Poisson distribution for binary outcomes to 
estimate rate ratios). Primary analyses were stratified by 
randomisation stratification factors. No adjustment was 
made for multiple testing (appendix pp 5–6). Analyses 
were done using Stata, version 15.1. This trial is registered 
with the International Standard Randomised Controlled 
Trial registry, ISRCTN84086586.
Role of the funding source
The funder of the study had no role in trial design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had the final 
responsibility to submit for publication. ECG and ASW 
had access to the raw data.
Results
Between Sept 17, 2014, and May 15, 2017, 3986 children 
with severe anaemia at admission to hospital were 
randomly assigned to receive enhanced supplementation 
versus standard treatment; three declined full consent 
(ie, written consent after verbal assent), and are excluded 
from all analyses (figure 1). 2418 (61%) of the 
3983 included children were from stratum A and had a 
haemoglobin concentration of less than 4 g/dL or other 
severity signs or both. Baseline characteristics were 
balanced between randomised groups (table 1, appendix 
p 22). Median age was 35 months (IQR 17–61) and 
haemoglobin was 4·5 g/dL (IQR 3·6–5·3). In the 
3983 children enrolled, a history of fever was common 
(3863, 97%), but fewer children had a documented 
temperature of more than 37·5°C at screening 
(1522, 38%) or signs of shock (1170, 29%). 2537 (64%) of 
3983 had Plasmodium falciparum malaria, but HIV 
infection (116 [3%] of 3983), microbiologically confirmed 
bacteraemia (125 [4%] of 3447), and severe malnutrition 
(75 [2%] of 3983) were uncommon (table 1). After batch 
genotyping, numbers with sickle cell disease increased 
from 466 (12%) to 1054 (27%), while 34 (1%) children 
reported as known sickle cell disease were AA or AS on 
genotyping. 
1901 (95%) of 1997 children randomly assigned to 
receive multivitamin multimineral supple ment versus 
1911 (96%) of 1986 children randomly assigned to receive 
iron and folate initiated their supplementation and 
treatment, respectively (appendix pp 23–24), both a 
Figure 2: Mortality and re-admissions through 180 days 
Mortality (A) and re-admission (C) in the multivitamin multimineral 
supplement and iron and folate groups, and mortality (B) and re-admission (D) 
in the co-trimoxazole and no co-trimazole groups. *These deaths occurred 
between timepoints on the x-axis. †Considered to have attended the 180-day 
visit as seen within the 120–240-day visit window: 3459 (99%) of 3484 seen at 
day 170 or later.
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median of 4 days (IQR 3–5) after admission. Numbers 
still reporting taking allocated supple mentation and 
treatment dropped to 1812 (91%) versus 1817 (91%), 
respectively, at 28 days, and to 1726 (86%) versus 
1713 (86%), respectively, at 90 days. At 28 days, significantly 
more carers reported that children had missed one or 
more doses of multivitamin multimineral supplement 
(625, 34%) than iron and folate (460, 25%; p<0·0001), 
with similar results at 90 days (687 [39%] versus 517 [30%] 
reporting missing one or more doses since last visit, 
respectively; p<0·0001). However, most returned relatively 
few sachets and tablets (appendix p 23–24).
1922 (96%) of 1994 children randomly assigned to 
co-trimoxazole initiated treatment a median of 4 days 
(IQR 3–5) days after admission. Numbers still reporting 
taking co-trimoxazole dropped to 1798 (90%) at 28 days, 
and to 1690 (85%) at 90 days. At 28 days, 466 (26%) carers 
reported that children had missed one or more doses 
of co-trimoxazole, with similar results at 90 days 
(522, 31%). However, most returned relatively few tablets 
(appendix p 24–25). Percentages missing doses of co-
trimoxazole were similar to percentages missing doses 
of iron and folate (appendix p 23–24).
Vital status at day 180, the primary endpoint, was 
unknown for 83 (4%) of 1997 children assigned to 
multivitamin multimineral supplement versus 81 (4%) of 
1986 children assigned to iron and folate, and 
83 (4%) of 1994 children assigned to co-trimoxazole versus 
81 (4%) of 1989 children assigned to no co-trimoxazole. By 
day 180, 166 (8%) children in the multivitamin 
multimineral supplement group versus 169 (9%) children 
in the iron and folate group had died (hazard ratio 
[HR] 0·97, 95% CI 0·79–1·21; p log-rank=0·81; figure 2; 
table 2). There was no evidence of interaction with 
other factorial randomisations (p>0·2). By day 180, 
172 (9%) children in the co-trimoxazole group versus 
163 (8%) children in the no co-trimoxazole group had died 
(1·07, 0·86–1·32; p log-rank=0·56; figure 2; table 3), with 
no evidence of interaction with other factorial random-
isations (p>0·2). 169 (48%) of 355 deaths could not be 
assigned a cause, primarily because they occurred out of 
hospital with little available information (appendix p 26). 
The most common assigned primary cause of death was 
specific infections (58 [16%] of 355), with 53 (15%) attributed 
to haematological conditions and 23 (6%) to lower 
respiratory tract infections.
For both randomisations, of 11 subgroups prespecified 
in the protocol (appendix pp 8, 10), and five prespecified 
in the statistical analysis plan (appendix pp 9, 11), only 
one (malnutrition) showed evidence of heterogeneity in 
the effect of multivitamin multimineral supplement 
versus iron and folate (p=0·01; rest p>0·1). However, 
this was driven by undernourished and malnourished 
subgroups, which were very small, and might be expected 
by chance because of the number of subgroups tested 
(n=31 across both randomisations). Malnutrition was 
defined using MUAC; considering MUAC as a con-
tinuous measure showed no evidence of heterogeneity in 
the effect of multivitamin multimineral supplement 
versus iron and folate (p=0·57). 
Children were discharged a median of 4 days (IQR 3–5) 
after admission in all randomised groups. Day 180 visits 
were completed for 1730 (87%) of 1997 children in the 
multivitamin multimineral supplement group versus 
1720 (87%) of 1986 children in the iron and folate group, 
and 1719 (86%) of 1994 children in the co-trimoxazole 
group versus 1731 (87%) of 1989 children in the no 
co-trimoxazole group.
339 (17%) of 1997 children in the multivitamin 
multimineral supplement group versus 353 (17%) of 
1986 children in the iron and folate group were re-
admitted within 180 days of randomisation (HR 0·96, 
MVMM  
(N=1997)
Iron and folate 
(N=1986)
Total participants 
(N=3983)
Hazard ratio 
(95% CI)
p value
Death
Before prescription 42 (2%) 52 (3%) 94 (2%) NA NA
28 days* 63 (3%) 77 (4%) 140 (4%) 0·81 (0·58–1·13) 0·22
90 days* 116 (6%) 122 (6%) 238 (6%) 0·94 (0·73–1·22) 0·66
180 days (primary outcome) 166 (8%) 169 (9%) 335 (8%) 0·97 (0·79–1·21) 0·81
Development of severe anaemia (haemoglobin 
<6 g/dL) post discharge*
392 (20%) 391 (19%) 783 (20%) 0·99 (0·86–1·13)† 0·88
Readmission to hospital* 339 (17%) 353 (17%) 692 (17%) 0·95 (0·82–1·10)† 0·48
Any serious adverse event* 489 (24%), 670 509 (26%), 681 998 (25%), 1351 0·95 (0·84–1·07) 0·40
Serious adverse event including anaemia 261 (13%), 352 276 (14%), 370 537 (13%), 722 NA 0·46‡
Serious adverse event including malaria 146 (7%), 165 142 (7%), 159 288 (7%), 324 NA 0·86‡
Serious adverse event including sepsis 81 (4%), 103 92 (5%), 110 173 (4%), 213 NA 0·39‡
Serious adverse event including haemoglobinuria 54 (3%); 66 57 (3%), 65 111 (3%), 131 NA 0·77‡
Data are n (%) or n (%), events, unless otherwise stated. All interaction p values between the factorial randomisations across time-to-event secondary outcomes are p>0·08 
(appendix p 33). MVMM=multivitamin multimineral supplements. NA=not applicable. *Prespecified secondary outcome. †From competing risks subhazard regression. 
‡Fisher’s Exact test.
Table 2: Secondary and other outcomes in the MVMM randomisation
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95% CI 0·83–1·11; p=0·59; figure 2; table 2). 
89 (4%) versus 86 (4%), respectively, were re-admitted 
two or more times before 180 days. Children increased 
their weight and MUAC post discharge, but there was no 
evidence that changes differed between multivitamin 
multimineral supplement and iron and folate groups at 
90 days (p=0·22 and p=0·48, respectively) or 180 days 
(p=0·65 and p=0·36, respectively; table 4).
338 (17%) of 1994 children in the co-trimoxazole group 
versus 354 (18%) of 1989 children in the no co-trimoxazole 
group were re-admitted within 180 days of randomisation 
(HR 0·96, 95% CI 0·83–1·11; p=0·61; table 3; figure 2). 
84 (4%) versus 91 (5%), respectively, were re-admitted 
two or more times before 180 days. Children increased 
their weight and MUAC post discharge, but there was no 
evidence that changes differed between co-trimoxazole 
and no co-trimoxazole groups at 90 days (p=0·13 and 
p=0·92, respectively) or 180 days (p=0·25 and p=0·40 
respectively; table 5).
489 (24%) of 1997 children in the multivitamin 
multimineral supplement group versus 509 (26%) of 
1986 children in the iron and folate group had one or 
Co-trimoxazole 
(N=1994)
No co-trimoxazole 
(N=1989)
Total participants 
(N=3983)
Hazard ratio 
(95% CI)
p value
Death
Before prescription 44 (2%) NA NA NA NA
28 days* 80 (4%) 60 (3%) 140 (4%) 1·34 (0·96–1·87) 0·09
90 days* 128 (6%) 110 (6%) 238 (6%) 1·17 (0·91–1·51) 0·22
180 days, primary outcome 172 (9%) 163 (8%) 335 (8%) 1·07 (0·86–1·32) 0·56
Development of severe anaemia (haemoglobin <6 g/dL) 
post discharge*
406 (20%) 277 (19%) 783 (20%) 1·09 (0·95–1·25)† 0·24
Readmission to hospital* 338 (17%) 354 (18%) 692 (17%) 0·95 (0·82–1·11)† 0·54
Any serious adverse event† 500 (25%), 673 498 (25%), 678 998 (25%), 1351 1·01 (0·89–1·15) 0·85
Serious adverse event including anaemia 280 (14%), 371 257 (13%), 351 537 (13%), 722 NA 0·31‡
Serious adverse event including malaria 126 (6%), 140 162 (8%), 184 288 (7%), 324 NA 0·03‡
Serious adverse event including sepsis 99 (5%), 114 74 (4%), 99 173 (4%), 213 NA 0·06‡
Serious adverse event including haemoglobinuria 50 (3%), 58 61 (3%), 73 111 (3%), 131 NA 0·29‡
Data are n (%) or n (%), events, unless otherwise stated. All interaction p values between the factorial randomisations across time-to-event secondary outcomes are p>0·08 
(appendix p 33). NA=not applicable. *Prespecified secondary outcome. †From competing risks subhazard regression. ‡Fisher’s Exact test.
Table 3: Secondary and other outcomes in the co-trimoxazole randomisation
MVMM Iron and folate Difference*
90 days
Change in weight from baseline, kg 1·25 (1·19 to 1·31), N=1764 1·19 (1·13 to 1·25), N=1758 0·05 (–0·03 to 0·14), p=0·22
Change in MUAC from baseline, cm 0·47 (0·42 to 0·51), N=1770 0·46 (0·42 to 0·51), N=1760 0·02 (–0·04 to 0·08), p=0·48
180 days
Change in weight from baseline, kg 1·82 (1·75 to 1·88), N=1676 1·79 (1·72 to 1·86), N=1682 0·02 (–0·07 to 0·12), p=0·65
Change in MUAC from baseline, cm 0·62 (0·58 to 0·66), N=1696 0·66 (0·62 to 0·71), N=1693 –0·03 (–0·09 to 0·03), p=0·36
Data are mean (95% CI), N or mean (95% CI), p value. MVMM=multivitamin multimineral supplements. MUAC=mid-upper arm circumference. *Estimated differences and 
confidence intervals obtained from a linear regression adjusted for baseline values.
Table 4: Changes in weight and MUAC in the MVMM randomisation
Co-trimoxazole No co-trimoxazole Difference*
90 days
Change in weight from baseline, kg 1·26 (1·20 to 1·32), N=1754 1·19 (1·13 to 1·25), N=1768 0·07 (–0·02 to 0·15), p=0·13
Change in MUAC from baseline, cm 0·45 (0·41 to 0·50), N=1754 0·48 (0·43 to 0·52), N=1776 0·00 (–0·05 to 0·06), p=0·92
180 days
Change in weight from baseline, kg 1·84 (1·77 to 1·91), N=1669 1·78 (1·71 to 1·84); N=1689 0·06 (–0·04 to 0·15); p=0·25
Change in MUAC from baseline, cm 0·62 (0·57 to 0·67); N=1685 0·66 (0·62 to 0·71); N=1704 –0·03 (–0·09 to 0·04); p=0·40
Data are mean (95% CI), N or mean (95% CI), p value. MUAC=mid-upper arm circumference. *Estimated differences and confidence intervals obtained from a linear 
regression adjusted for baseline values.
Table 5: Changes in weight and MUAC in the co-trimoxazole randomisation
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more serious adverse events (p=0·40; table 2; 
appendix p 27–32). In the multivitamin multimineral 
and iron and folate groups, respectively, 670 versus 
681 serious adverse events occurred, of which 475 versus 
491 were re-admissions to hospital. There was no 
evidence of differences between the two groups in 
anaemia, malaria, sepsis, or haemoglobinuria serious 
adverse events (p>0·3; table 2). 500 (25%) of 1994 children 
in the co-trimoxazole group versus 498 (25%) of 
1989 children in the no co-trimoxazole group had 
one or more serious adverse event (p=0·85; table 3; 
appendix p 27–32), for a total number of events of 
673 versus 678, of which 472 versus 494 were re-
admissions to hospital, respectively. There was no 
evidence of differences between co-trimoxazole versus 
no co-trimoxazole in anaemia or haemoglobinuria 
serious adverse events (p>0·28) and weak evidence for 
a difference in sepsis serious adverse events (p=0·06), 
but children randomly assigned to co-trimoxazole had 
significantly fewer malaria serious adverse events 
(p=0·03; table 3). There was no evidence of interactions 
between randomisations for these other secondary 
outcomes (pheterogeneity>0·08, appendix p 33).
After discharge, there was no evidence of difference 
between the multivitamin multimineral supplement and 
iron and folate groups in the proportions of patients 
with positive malaria slides (p>0·4; appendix p 12), with 
possible malaria infection (positive malaria slide or 
reporting having had an acute febrile illness or having 
taken antimalarials; p>0·3; appendix p 13) or possible 
bacterial infection (severe infection, or reporting having 
received antibiotics or having an acute febrile illness; 
p>0·4; appendix p 14) or severe bacterial infection 
(p=0·82; appendix p 15). At 28 days, co-trimoxazole 
reduced the proportions of patients with positive malaria 
slides (p<0·001; appendix p 12), and possible 
malaria infection (p=0·02; appendix p 13), but there was 
no evidence of differences at days 90 or 180 (p>0·1), and 
no evidence of differences in possible or severe bacterial 
infections (p>0·1; appendix pp 14–15).
Few grade 3–4 adverse events for co-trimoxazole, 
multivitamin multimineral supplement, or standard iron 
and folate were reported as probably or possibly related 
by site clinicians (co-trimoxazole n=10; multivitamin 
multimineral supplement n=4; iron and folate n=1; 
appendix p 34). None were judged to be related on 
independent clinical review. Results of primary and 
secondary outcomes restricted to patients alive at the 
minimum of discharge or 5 days from randomisation in 
whom the interventions were neither mandated nor 
contraindicated were similar (appendix p 35).
There was no evidence of difference between the 
multivitamin multimineral supplement versus iron and 
folate groups in the development of severe anaemia; 
p=0·16; table 2) or in the proportions achieving correction 
of anaemia (>9 g/dL) after discharge (p>0·2; figure 3; 
appendix p 38), or in the mean change in haemoglobin 
from baseline (p>0·2; appendix p 16). There was also no 
evidence of difference between co-trimoxazole versus 
no co-trimoxazole in the development of severe anaemia 
after discharge (p=0·87, table 3), or in the proportions of 
children achieving correction of anaemia (>9 g/dL; 
figure 3) after discharge (p>0·3), or in the mean change 
in haemoglobin from baseline (p>0·4; appendix p 17). 
Overall, 2871 (74%) children had already achieved a 
haemoglobin concentration of at least 6 g/dL by 48 h and 
665 (17%) children had achieved a concentration of more 
than 9 g/dL (figure 3; appendix pp 16–17, 38). Discharge 
haemoglobin concentrations were not available, but by 
28 days after discharge, they had increased to 3352 (92%) 
and 2100 (58%), respectively, and subsequently remained 
fairly stable.
To explore the effect of iron dose, we did exploratory 
subgroup analyses by age group. Children younger than 
age 2 years (1400, 35%) received 10 mg of iron if randomly 
assigned to multivitamin multimineral supplement 
versus 25 mg of iron if randomly assigned to iron and 
Figure 3: Proportions of children with haemoglobin concentrations of less than 6 g/dL, 6–9 g/dL, and more 
than 9 g/dL over 180 days in multivitamin multimineral supplement and iron and folate groups (A) and 
co-trimoxazole and no co-trimazole groups (B)
Numbers can be found in the appendix (p 38).
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folate; children older than age 2 years received 10 mg 
versus 60 mg of iron, respectively. Because even 60 mg 
of iron might be subtherapeutic in children older 
than 5 years, we considered children aged 2–5 years 
(2459, 62%) and children older than 5 years (124, 3%) 
separately. Firstly, in this exploratory analysis there was 
no evidence of heterogeneity in the lack of effect of 
multivitamin multimineral supplement versus iron and 
folate on mortality at day 180 across these age groups 
(pheterogeneity=0·96; HR 0·97, 95% CI 0·67–1·40 for <2 years; 
HR 0·95, 0·73–1·26 for 2–5 years; and HR 1·09, 
0·42–2·81 for >5 years), and no evidence of an interaction 
for serious adverse events (pheterogeneity=0·62). Furthermore, 
despite the substantial difference in iron doses received 
in the different age groups, haemoglobin recovery was 
similar in children receiving multivitamin multimineral 
supplement and iron and folate in each of the age groups 
(appendix p 18). 
To assess whether this effect could be driven by the 
fact that many children received a transfusion during 
the trial, and hence iron absorption from the transfusion 
might have addressed underlying iron deficiency, in 
further exploratory analyses we compared haemoglobin 
recovery in children in the stratum with a haemoglobin 
concentration of 4–6 g/dL, and no severity signs 
randomised to immediate versus triggered transfusion, 
splitting the triggered transfusion group by (non-
randomised) receipt of transfusion (appendix p 19). 
Adjusting for predictors of receiving a transfusion, 
there was no evidence that the lack of effect of 
multivitamin multimineral supplement versus iron 
and folate on haemoglobin recovery at days 28, 90, or 
180 varied by whether or not, and when, a transfusion 
was received (p>0·6). In a final exploratory analysis, we 
considered the effect of age subgroup (as a proxy for 
iron dose) on malaria (appendix p 20), but found no 
evidence that the lack of effect of multivitamin 
multimineral supplement versus iron and folate varied 
by age group for either slide positive malaria 
(pheterogeneity>0·20) or possible malaria (p>0·45). In 
particular, higher rates of malaria with higher iron 
doses were not evident within any of these subgroups at 
any timepoint (p>0·2).
Discussion
In this large multicentre trial, we observed no overall 
differences in mortality over 180 days among children 
with severe anaemia receiving multivitamin multi-
mineral supplement versus iron and folate treatment or 
receiving co-trimoxazole prophylaxis. the only evidence 
for differences across various outcomes were reductions 
in malaria and in sepsis serious adverse events in 
children randomly assigned to co-trimoxazole. Overall, 
we found that children admitted with severe anaemia 
were at high risk of poor outcomes, including 
8% mortality within 6 months of admission (6% in the 
first 90 days), and high rates of re-admission post 
discharge (17%). Establishing that novel inter ventions 
are urgently required for this high-risk group of children.
This was a pragmatic trial testing the clinical 
effectiveness of practical interventions that could be 
implemented at scale, rather than the efficacy of the 
drugs. The strength and generalisability of the trial lies 
in its broad eligibility criteria, high adherence to 
randomised interventions, and completeness of follow-
up to 28 days and 180 days. Large subgroups of children 
with malaria and sickle cell disease were included, 
making the absence of benefit generalisable to areas of 
Africa where these conditions are prevalent. Although 
outcomes in children with sickle cell disease have 
recently been recognised as a major burden on health 
services,26 in our study, mortality of children in sickle 
cell disease was lower than in children without sickle 
cell disease, suggesting that the disease did not dispro-
portionately affect our results. Limitations of the study 
include the lack of definitive diagnoses in many children 
dying at home and that mortality was lower than 
anticipated, possibly due to the provision of standard 
medications for all participants by the trial and the close 
contact with the patients during follow-up so new 
illnesses requiring re-admission were identified early in 
their course. Nevertheless, the 95% CI suggested that 
relative reductions of more than 20% (absolute benefits 
of >1·8%) associated with the interventions can be 
reliably excluded given the results of this trial. However, 
the number of re-admissions were substantial (which 
might possibly have averted some deaths), and so the 
trial had good power to detect modest effects on this 
outcome. Although in the protocol, we were unable to 
obtain haemoglobin concentration at discharge for 
most children because many parents refused this test 
after children recovered. the substantial increases in 
haemoglobin concentration from 48 h to 28 days post 
admission (appendix pp 16–17) makes it difficult to assess 
the optimal time for future interventions to target. 
We did not have funding to estimate micronutrient 
deficiencies at baseline. We did not include a placebo 
control for either intervention; the inclusion of such 
a control could have affected attribution of illness 
episodes to infection for co-trimoxazole prophylaxis, 
although rates were constant over follow-up, before and 
after co-trimoxazole prophylaxis was being prescribed 
(appendix p 15). Adherence was imperfect, with around 
one-third of participants reporting missing any doses, 
although the numbers of tablets returned suggested that 
most were only missing occasional doses. This proportion 
of adherence probably reflects usual practice by carers 
and children. We found expected effects of co-trimoxazole 
on malaria, sepsis, and fevers, which suggests that 
sufficient active ingredient was being ingested to identify 
an effect. Lastly, given the scarcity of available resources, 
randomisation was done at admission, at the same 
time as the transfusion randomisations. The fact that a 
small proportion of children (3%, appendix p 23) died or 
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absconded before they could start the intervention means 
that our intention-to-treat estimates are slightly biased 
towards the null compared with those that would have 
been obtained from a trial randomising at discharge, 
but the factorial design ensures balance across the 
transfusion interventions.
Iron supplementation and treatment has been 
controversial in children in malaria-endemic areas. A 
community-based randomised controlled trial in Pemba, 
Zanzibar, showed a higher risk for serious events 
including death or admission to hospital with malaria in 
iron (12·5 mg) plus folic acid versus placebo (actual 
difference 12%, 95% CI 2–23%),27 resulting in recom-
mendations that iron and folic acid should be targeted to 
children with anaemia who are at risk of iron deficiency.28,29 
However, the diagnosis of iron deficiency is unreliable in 
children who are febrile with an acute inflammatory 
state secondary to infection.30–32 Furthermore, owing to 
the significant burden that testing children for iron 
status places on health-care services, WHO revised their 
recommendations in 2011, indicating children receiving 
iron in malaria-endemic areas should be concurrent with 
“measures to prevent, diagnose and treat malaria”.33 This 
approach was subsequently supported by a trial from 
Ghana34 and reinforced by a Cochrane systematic review35 
showing no overall harm for children treated with iron 
if given alongside malaria diagnosis, treatment, and 
insecticide-treated bednets. In TRACT we compared 
multivitamin multimineral supplement containing the 
equivalent of supplementary iron and folate doses to 
standard treatment doses in four centres with differing 
levels of malaria endemicity. Half of the children were 
also randomly assigned to receive concurrent infection 
prophylaxis with co-trimoxazole. We found no evidence of 
differences in haemoglobin recovery by nutritional 
strategy (appendix p 18) nor evidence of an increased risk 
of mortality or serious adverse events (predominantly 
hospitalisation or death) or malaria (appendix p 20) in 
children receiving higher doses of iron, or any interactions 
in children receiving infection prophylaxis or not. We also 
found no interaction with transfusion received (including 
dose) or not (appendix pp 8, 10), and haemoglobin 
recovery occurred similarly with multi vitamin multi-
mineral supplement and iron and folate even in children 
who were not transfused (appendix p 19). 
We found no evidence that supplementation to reduce 
deficiencies previously identified as associated with 
severe anaemia3 had any effect on any outcome; 
furthermore, contrary to other reports,36 multivitamin 
multimineral supplement was significantly less accept-
able to carers and children than standard iron and folate. 
Variation in the overall dose of iron received by 
randomised intervention and by age allowed us to make 
two important observations. First, in children living in 
malarious areas, we saw no demonstrable increase in the 
risks of infection (including malaria and severe sepsis) or 
death in children receiving higher doses. Second, iron 
appeared to have a limited role in recovery from severe 
anaemia. The failure of orally administered iron to 
improve haematological indices or outcomes in this 
population might be due to inhibition of ferroportin-
mediated systemic iron absorption.37 In the presence of 
infection and inflammation, hepatic hepcidin production 
is upregulated, effectively causing iron to remain trapped 
within enterocytes and ultimately be excreted faecally. 
Although this questions the merit of orally administered 
iron (or micronutrients) in the management of severe 
anaemia we did not include a control and placebo group 
because iron and folate is considered standard treatment. 
The choice of co-trimoxazole for infection prophylaxis, 
rather than co-trimoxazole plus an antimalarial, was 
based on three considerations. First, as in HIV-infected 
children,10 we hypothesised that it might improve long-
term morbidity and mortality by preventing recurrent 
bacterial infections, a major risk factor in this population. 
Second, prophylactic co-trimoxazole reduces malaria 
infection,38,39 a key risk factor for recurrence of severe 
anaemia. Finally, a single dose daily of a medicine is 
preferable to polypharmacy, where the ideal regimen for 
both bacterial and malaria prophylaxis in this large 
heterogenous population is unknown. For example, in 
children with sickle cell disease (25% of this trial cohort), 
routine prophylaxis for malaria prevention would use 
daily sulfadoxine and pyrimethamine; if used with co-
trimoxazole, this might lead to overdosing children 
on sulphonamides, which have long half-lives and are 
present in both sulphadoxine and pyrimethamine, and 
co-trimoxazole. However, despite the hypothesised 
benefits, it is notable that co-trimoxazole prophylaxis 
appears to be protective only in children with HIV,8,40 
with no evidence of mortality benefits now having been 
robustly shown in trials in severe malnutrition12 
and severe anaemia, despite both showing reductions in 
some infection events that nevertheless did not translate 
into mortality reductions. This might be related to 
deficits in memory CD4 T cells in children infected 
with HIV even after starting antiretroviral therapy and 
benefits of co-trimoxazole on inflammation.41 Whether 
an alternative antibiotic such as azithromycin42 might 
have greater effects is unclear,43 particularly since 
the burden of non-malarial febrile illness appeared 
relatively low.
In conclusion, although our findings highlight the 
burden that severe anaemia continues to place on 
overstretched health services in Africa, they do not 
support the use of multivitamin multimineral supple-
ment, iron and folate, or co-trimoxazole to improve poor 
outcomes after discharge in children. Because we were 
able to examine dose of iron and found haemoglobin 
recovery to be similar at all doses and even in children 
who did not receive a transfusion, our trial also raises 
questions about the use of iron treatment at all, calling 
for future trials incorporating a placebo or control group 
into the micronutrient arm of a study.
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